TABLE 2.
Clinical and immune characteristics
| Control | GM-CSF Ab Lo | GM-CSF Ab Hi | |
|---|---|---|---|
| n | 15 | 12 | 15 |
| Age, median (range) | 13.5 (8.5–18.9) | 13.3 (8.2–18.0) | 15.3 (9.3–18.9) |
| Sex | 67% female | 17% female | 27% female |
| Serum GM-CSF Ab, μg/mL (range) | 0.57 (0.32–0.64) | 0.25 (0.2–0.73) | 9.4* (2.6–13.2) |
| Montreal classification of disease | |||
| Terminal ileum (L1) | L1: 1 (8%) | L1: 1 (7%) | |
| Colon (L2) | L2: 2 (17%) | L2: 2 (13%) | |
| Ileocolon (L3) | L3: 9 (75%) | L3: 12 (80%) | |
| Upper GI only (L4) | L4: 0 | L4: 0 | |
| Nonstricturing, nonpenetrating (B1) | B1: 12 (100%) | B1: 13 (86%) | |
| Stricturing (B2) | B2: 0 | B2: 1 (7%) | |
| Penetrating (B3) | B3: 0 | B3: 1 (7%) | |
| Age at diagnosis ≤16 y (A1) | A1: 100% | A1: 100% | |
| Medications | |||
| Corticosteroids | 1 (8%) | 2 (13%) | |
| Oral immunomodulator | 10 (83%) | 10 (67%) | |
| 5-Aminosalicylate | 7 (58%) | 3 (20%) | |
| Antibiotics | 1 (8%) | 4 (27%) | |
| Infliximab | 1 (8%) | 9 (60%)** | |
| CARD15 mutation | 1 (7%) | 4 (33%) | 3 (20%) |
| Clinical remission frequency | 10 (83%) | 9 (60%) | |
| Fecal S100A12, μg/kg (range) | 70 (59–103) | 5,500 (2050–11,000) | 5050*** (100–16,250) |
| Serum lipopolysaccharide-binding protein, μg/mL (range) | 22.2 (11.6–47.7) | 30.0 (20.8–46.8) |
GM-CSF Ab Lo = patients with CD with serum GM-CSF autoantibody <1.6 μg/mL, GM-CSF Ab Hi = patients with CD with serum GM-CSF autoantibody ≥1.6 μg/mL. Values for GM-CSF Ab, S100A12, and LBP are given as the median (IQR). GM-CSF Ab = granulocyte macrophage-colony-stimulating factor autoantibodies; GM-CSF Ab Lo = low granulocyte macrophage-colony-stimulating factor autoantibodies; GM-CSF Ab Hi = high granulocyte macrophage-colony-stimulating factor autoantibodies; LBP = lipopolysaccharide-binding protein.
*
P < 0.001 vs control and GM-CSF Ab Lo group;
**
P < 0.05 vs GM-CSF Ab Lo group;
***
P < 0.05 vs control.